通过无细胞DNA扫描和炎症微环境调制来治疗自身免疫性疾病的炎症反应性多离子复合囊泡
Renxiang Zhou1, Yang Zhou1, Mengyuan Yin1
1Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science & Technology, Soochow University, Suzhou 215123, China.
ACS nano
|October 16, 2024
概括
一些囊泡清理无细胞DNA,并提供甲状腺素以向自身免疫性疾病中的炎症. 在临床前模型中,这种双重作用降低了炎症并促进了组织修复.
科学领域:
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
- 纳米医学是一种纳米医学.
背景情况:
- 无细胞DNA (cfDNA) 清理显示出治疗自身免疫性疾病 (AID) 的潜力.
- 目前的方法与向cfDNA清理和解决与cfDNA无关的炎症作斗争.
- 开发有效的抗炎药物输送系统仍然是一个挑战.
研究的目的:
- 开发用于向cfDNA清理和药物输送的对炎症有反应的多离子复合囊泡 (PICsomes).
- 将cfDNA清理与甲状腺素 (MTX) 输送相结合,以改善自身免疫性疾病的管理.
- 在自身免疫性疾病的临床前模型中评估PICsomes的疗效.
主要方法:
- 通过自组装PEGylated guanidine polypeptide (PEG-PG) 和cis-aconitic无水化物修饰的poly-L-lysine (PC) 来制造PICsomes.
- 在PICsomes中封装甲基酸二盐.
- 在炎症微环境中评估PIC某些行为,并在AID小鼠模型中评估治疗效果.
主要成果:
- PICsomes在炎症组织中表现出长时间的循环和积累.
- 炎症微环境触发了PIC的一些解体,释放了PEG-PG和MTX.
- 结合cfDNA清理和MTX输送,在原诱导的关节炎和结肠炎模型中有效抑制炎症并促进组织修复.
结论:
- 具有炎症反应的PICsomes为针对性cfDNA清理和自身免疫性疾病中的药物输送提供了一种新的策略.
- 这种cfDNA清除和免疫抑制的双重机制表明了显著的治疗潜力.
- 这种方法有望改善自身免疫性疾病的治疗结果.
相关概念视频
Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Autoimmune Disorders
392
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
392
T Cell Types and Functions
959
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
959
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


